ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS

Proteasome inhibition sensitizes glioma cells to TMZ and RT, providing a novel therapeutic strategy for ndGBM. MRZ, an irreversible, brain-penetrant, pan-proteasome inhibitor with anti-glioma activity was combined with standard-of-care (SOC) concomitant TMZ/RT followed by adjuvant TMZ in ndGBM (NCT0...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Bota, Daniela A, Kesari, Santosh, Piccioni, David, Aregawi, Dawit, Roth, Patrick, Stupp, Roger, Desjardins, Annick, Reich, Steven D, Elias, Ileana, Li, Mingyu, Levin, Nancy, Winograd, Benjamin, Mason, Warren
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216380/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.073
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge